Kura Oncology (NASDAQ:KURA) Insider Sells $94,819.68 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 11,208 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the transaction, the insider owned 226,931 shares of the company’s stock, valued at $1,919,836.26. The trade was a 4.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Teresa Brophy Bair also recently made the following trade(s):

• On Friday, November 14th, Teresa Brophy Bair sold 8,804 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total value of $98,428.72.

Kura Oncology Stock Up 2.2%

KURA stock opened at $8.22 on Friday. The company has a market cap of $715.30 million, a price-to-earnings ratio of -3.31 and a beta of 0.25. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $12.49. The business has a 50 day moving average price of $10.21 and a two-hundred day moving average price of $9.04. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The company had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. Analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the company. UBS Group AG lifted its holdings in Kura Oncology by 118.3% during the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after purchasing an additional 574,455 shares during the last quarter. Vanguard Group Inc. increased its position in Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after buying an additional 39,105 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Kura Oncology by 41.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,363 shares of the company’s stock worth $482,000 after buying an additional 13,579 shares in the last quarter. Merit Financial Group LLC boosted its position in shares of Kura Oncology by 124.0% in the fourth quarter. Merit Financial Group LLC now owns 22,499 shares of the company’s stock valued at $234,000 after acquiring an additional 12,454 shares during the period. Finally, Xcel Wealth Management LLC grew its stake in shares of Kura Oncology by 16.2% in the fourth quarter. Xcel Wealth Management LLC now owns 118,846 shares of the company’s stock valued at $1,235,000 after acquiring an additional 16,525 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KURA. Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Zacks Research downgraded Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. UBS Group raised their price objective on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 14th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Tuesday, January 13th. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.